Octave Specialty Group (OSG) 주식 개요
보험 지주 회사인 옥타브 스페셜티 그룹은 주로 미국과 영국에서 특수 재산 및 상해 보험 사업을 영위하고 있습니다. 자세히 보기
OSG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Octave Specialty Group, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$5.54 |
| 52주 최고가 | US$10.38 |
| 52주 최저가 | US$3.88 |
| 베타 | 0.79 |
| 1개월 변동 | 20.70% |
| 3개월 변동 | 0.36% |
| 1년 변동 | -31.18% |
| 3년 변동 | -60.74% |
| 5년 변동 | -64.12% |
| IPO 이후 변동 | -72.84% |
최근 뉴스 및 업데이트
내러티브 업데이트 • May 13
OSG: Completed Buybacks Will Tighten Float And Support Future Upside Potential
Analysts have kept their $12.00 price target for Octave Specialty Group unchanged, citing updated assumptions that include a slightly lower discount rate, adjusted revenue growth expectations of 15.54%, a profit margin estimate of 10.93%, and a projected future P/E of 12.26x. What's in the News From October 1, 2025 to December 31, 2025, Octave Specialty Group repurchased 3,142,554 shares for US$27.34 million, representing 6.73% of its shares.내러티브 업데이트 • Apr 22
OSG: Completed Buybacks Will Tighten Float And Support Future Upside Potential
Analysts have kept their $12.00 price target for Octave Specialty Group unchanged, noting only slight adjustments to underlying assumptions such as discount rate, revenue growth, profit margin, and future P/E, which they view as offsetting each other overall. What's in the News Between October 1, 2025 and December 31, 2025, Octave Specialty Group repurchased 3,142,554 shares, representing 6.73% of its shares, for $27.34 million under its existing buyback program (Key Developments).내러티브 업데이트 • Apr 07
OSG: Share Repurchases Will Tighten Float And Support Future Upside Potential
Analysts now maintain their price target for Octave Specialty Group at $12.00, citing similar fair value and margin assumptions, with only modest adjustments to revenue growth, the discount rate, and future P/E inputs. What's in the News Completed share repurchase of 4,371,886 shares, representing 9.33% of outstanding shares, for a total of $42.45 million under the buyback announced on November 12, 2024 (Key Developments).Recent updates
내러티브 업데이트 • May 13
OSG: Completed Buybacks Will Tighten Float And Support Future Upside Potential
Analysts have kept their $12.00 price target for Octave Specialty Group unchanged, citing updated assumptions that include a slightly lower discount rate, adjusted revenue growth expectations of 15.54%, a profit margin estimate of 10.93%, and a projected future P/E of 12.26x. What's in the News From October 1, 2025 to December 31, 2025, Octave Specialty Group repurchased 3,142,554 shares for US$27.34 million, representing 6.73% of its shares.내러티브 업데이트 • Apr 22
OSG: Completed Buybacks Will Tighten Float And Support Future Upside Potential
Analysts have kept their $12.00 price target for Octave Specialty Group unchanged, noting only slight adjustments to underlying assumptions such as discount rate, revenue growth, profit margin, and future P/E, which they view as offsetting each other overall. What's in the News Between October 1, 2025 and December 31, 2025, Octave Specialty Group repurchased 3,142,554 shares, representing 6.73% of its shares, for $27.34 million under its existing buyback program (Key Developments).내러티브 업데이트 • Apr 07
OSG: Share Repurchases Will Tighten Float And Support Future Upside Potential
Analysts now maintain their price target for Octave Specialty Group at $12.00, citing similar fair value and margin assumptions, with only modest adjustments to revenue growth, the discount rate, and future P/E inputs. What's in the News Completed share repurchase of 4,371,886 shares, representing 9.33% of outstanding shares, for a total of $42.45 million under the buyback announced on November 12, 2024 (Key Developments).내러티브 업데이트 • Mar 23
OSG: Share Repurchases Will Support Future Upside Potential
Analysts now hold their price target for Octave Specialty Group at $12.00, reflecting slightly updated assumptions for revenue growth, profit margins, discount rate, and future P/E that fine tune rather than overhaul their prior view. What's in the News Completed share repurchase program with a total of 4,371,886 shares bought back for $42.45 million, representing 9.33% of shares under the buyback announced on November 12, 2024 (Key Developments).내러티브 업데이트 • Mar 09
OSG: Share Repurchases And Auditor Shift Will Support Future Upside Potential
Analysts have reduced their price target on Octave Specialty Group from $15.00 to $12.00, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News Completed share repurchase of 4,371,886 shares in total, representing 9.33% of shares, for $41.69 million under the buyback announced on November 12, 2024.내러티브 업데이트 • Feb 22
OSG: Auditor Transition And Execution Will Support Future Upside Potential
Analysts have adjusted their price target on Octave Specialty Group to $15.00. This change reflects updated assumptions around slightly higher projected revenue growth, a modestly stronger profit margin, and a lower future P/E multiple.내러티브 업데이트 • Feb 07
OSG: ArmadaCare Execution And Organic Expansion Will Support Future Upside Potential
Analysts have raised their price target on Octave Specialty Group to $15 from $10, citing updated models that incorporate recent earnings, higher assumed organic growth, and the impact of the ArmadaCare deal. Analyst Commentary While the new US$15 price target signals higher modeled value for Octave Specialty Group, not all of the commentary behind the scenes is purely optimistic.내러티브 업데이트 • Jan 24
OSG: Higher Growth Assumptions And ArmadaCare Integration Will Drive Future Upside
Narrative Update Analysts have lifted their price target on Octave Specialty Group to US$15 from US$10, citing refreshed models that factor in higher assumed organic growth, the ArmadaCare acquisition and recent quarterly performance. Analyst Commentary While the higher US$15 target reflects more constructive modeling around organic growth and the ArmadaCare acquisition, not all commentary skews optimistic.
내러티브 업데이트 • Jan 09
OSG: Earnings Beat And ArmadaCare Integration Will Support Long-Term Share Gains
Analysts have raised their price target on Octave Specialty Group by $5 to $15, citing updated models that incorporate Q3 earnings, revised assumptions for organic growth, and the expected impact of the ArmadaCare transaction. Analyst Commentary Bullish Takeaways Bullish analysts point to the updated Q3 earnings model as support for the new US$15 price target, arguing that current valuation better reflects Octave Specialty Group's recent financial results.내러티브 업데이트 • Dec 25
OSG: Earnings Beat And Deals Will Drive Long-Term Shareholder Upside
Analysts raised their price target for Octave Specialty Group by $5, increasing it to $15 from $10. They cited updated models that reflect stronger assumed organic growth following an earnings beat and recent strategic transactions, which they believe support a path to sustained elevated expansion.내러티브 업데이트 • Dec 11
OSG: Q3 Earnings Beat Will Support Long-Term Shareholder Value Expansion
Analysts raised their price target on Octave Specialty Group to $15 from $10, citing updated models that reflect stronger than expected Q3 performance, higher assumed organic growth, and incremental upside from recent strategic deals. Analyst Commentary Analysts note that the revised price target for Octave Specialty Group is grounded in tangible improvements to the company’s growth profile, as well as rising confidence in management’s ability to execute on recent strategic initiatives.내러티브 업데이트 • Nov 27
OSG: Sustained Organic Expansion Will Drive Long-Term Shareholder Value
Analysts have raised their price target for Octave Specialty Group, increasing it by $5 to reflect stronger than expected organic growth and recent strategic acquisitions. Analyst Commentary Following the recent price target increase, analysts have provided additional context regarding their views on Octave Specialty Group's prospects.내러티브 업데이트 • Nov 13
AMBC: Revenue Momentum and Armada Acquisition Will Drive Further Share Upside
Analysts have raised their price target for Octave Specialty Group from $14.67 to $16.33. They cite stronger projected revenue growth and improved profitability metrics in their updated outlook.Seeking Alpha • Oct 03
Ambac: Surprise Acquisition Changes Outlook (Rating Downgrade)
Summary Ambac is downgraded to Hold following the surprise $250M ArmadaCare acquisition after selling its legacy guarantee business. The new deal adds product diversification and potential growth, but reintroduces debt and increases risk to the balance sheet. Management maintains 2028 adjusted EBITDA guidance at $80M–$90M, despite the significant size of the ArmadaCare acquisition. I recommend waiting for a lower entry price below $7 or more clarity in Q3 results before considering AMBC a Buy again. Read the full article on Seeking Alpha새로운 내러티브 • Jul 20
US Infrastructure Spending And Automation Will Unlock Insurance Potential
Diversification into specialty insurance and tech-driven operations is improving revenue stability, earnings quality, and operational efficiency.Seeking Alpha • Mar 01
Ambac: Despite EPS Miss, It's A Growth Company
Summary Ambac Financial Group saw a stock decline after an earnings miss for Q4. Such a sell-off overlooks the fundamental improvements: profitable underwriting and the build-out of a higher-ROE distribution platform. The sale of the legacy business remains to be approved by Wisconsin, creating a thorn in AMBC's side for the moment. Management, however, was eager about the growth ahead; the current price is a small P/E for earnings in just a few years. Read the full article on Seeking AlphaSeeking Alpha • Dec 27
Ambac Financial: Don't Get Lost In The Weeds; It's Working
Summary Ambac Financial Group has shifted from guarantee insurance to specialty property-casualty insurance and distribution. Despite a drop in tangible book value per share, the sale of the legacy business and recent acquisitions are expected to improve financials and boost earnings. Ambac Financial faces risks from recent hurricanes and potential delays in the legacy business sale approval, but overall outlook remains positive. I maintain a Buy rating on AMBC stock, believing Ambac's turnaround strategy will lead to better capitalization and improved earnings, offering a favorable risk-reward asymmetry. Read the full article on Seeking AlphaSeeking Alpha • Jul 30
Ambac Financial: Unbundling The Recent Sale And The New Acquisition
Summary Ambac sold its Financial Guarantee business to Oaktree at a disappointing valuation, causing a 20% drop in stock price. The company reinvested proceeds into acquiring a majority stake in Beat Capital Partners for $280 million at a generous valuation, raising concerns among investors. Despite the negative stock reaction, a new valuation framework suggests a fair value per share of around $15, indicating a 20% upside potential. Read the full article on Seeking AlphaSeeking Alpha • Mar 27
Ambac: Finally Shaking Off The Great Financial Crisis
Summary Ambac Financial Group has undergone a turnaround after the 2008 Financial Crisis, improving its financial position and evolving its business model. The company's balance sheet appears healthy and able to meet upcoming obligations, with a new focus on specialty property-casualty insurance. AMBC is positioning itself to underwrite its products through a technology-driven MGA model, aiming to take advantage of the growing US market with attractive loss ratios. Yet, investors should remember that the discount exists for a reason, given how a recession could particularly affect a company like this. Read the full article on Seeking AlphaSeeking Alpha • Jan 10
Ambac: Releasable Liquidity And SOTP Analysis Reveals Upside Potential
Summary Ambac is a complex company with a financial guarantees business and a new specialty P&C insurance business. We run a comparison with MBIA to compute releasable liquidity from the FG business that may be paid out as a special dividend. Ambac may benefit from a liquidity release or a sale, but the bulk of its value lies in its new businesses. Read the full article on Seeking AlphaSeeking Alpha • Sep 24
Ambac Financial Group Inc: Debt Trap Disguised As Value Opportunity
Summary Ambac Financial Group Inc is trading at low multiples but has a significant amount of debt that is impacting its expansion capacities. AMBC operates through two divisions, Everspan and Cirrata, and presents itself as an opportunity in the growing specialty coverage market. The company's high debt levels and inconsistent bottom line make it a risky investment, and the share price is expected to decline further. Read the full article on Seeking AlphaSeeking Alpha • Jun 14
Ambac Remains Discounted By An Apprehensive Market
Summary Ambac has seen significant price appreciation since the announced settlement with Bank of America and Nomura Holdings. Alongside aggressive growth from Cirrata, shareholders can expect effective organic and inorganic growth from Ambac. Despite these factors, Ambac still trades at a 23% undervaluation, leading me to rate the company a 'buy'. Read the full article on Seeking AlphaSeeking Alpha • Jan 03
Ambac settles with Nomura, closing financial crisis-era RMBS lawsuits
Ambac Financial Group (NYSE:AMBC) said Tuesday its Assurance Corporation subsidiary (AAC) entered into a settlement agreement with Nomura (NYSE:NMR) that will give AAC $140M. The settlement brings to an end all of Ambac's (AMBC) legacy residential mortgage-backed securities representation and warranty litigation that arose from the 2008 financial crisis. In October, Bank of America (BAC) agreed to pay Ambac $1.8B to settle litigation related to mortgage company Countrywide's collapse during the crisis. The settlement exceeds the amount of recovery recorded on Ambac's (AMBC) Q3 2022 GAAP financial statements attributed to the Nomura (NMR) litigation. As a result, the company will record a gain of ~$43M in its Q4 financial statement. Last month, Street Insider reported that Assured Guaranty (AGO) and Ambac Financial (AMBC) had made bids for rival MBIA (MBI).분석 기사 • May 12
Just In: One Analyst Has Become A Lot More Bullish On Ambac Financial Group, Inc.'s (NYSE:AMBC) Earnings
Celebrations may be in order for Ambac Financial Group, Inc. ( NYSE:AMBC ) shareholders, with the covering analyst...주주 수익률
| OSG | US Insurance | US 시장 | |
|---|---|---|---|
| 7D | -5.5% | -0.7% | 2.5% |
| 1Y | -31.2% | -8.8% | 26.4% |
수익률 대 산업: OSG은 지난 1년 동안 -8.8%의 수익을 기록한 US Insurance 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: OSG은 지난 1년 동안 26.4%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| OSG volatility | |
|---|---|
| OSG Average Weekly Movement | 14.8% |
| Insurance Industry Average Movement | 4.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: OSG의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.
시간에 따른 변동성: OSG의 주간 변동성(15%)은 지난 1년 동안 안정적이었지만 US 종목 중 상위 75%보다 높습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1991 | 483 | Claude LeBlanc | www.octavegroup.com |
보험 지주 회사인 옥타브 스페셜티 그룹은 주로 미국과 영국에서 특수 손해보험 사업을 영위하고 있습니다. 이 회사는 특수 손해보험과 보험 유통의 두 가지 부문으로 운영되고 있습니다. 특수 재산 및 상해 보험 부문은 상업 및 개인 책임 위험에 중점을 둔 특수 재산 및 상해 프로그램 보험을 제공합니다.
Octave Specialty Group, Inc. 기초 지표 요약
| OSG 기초 통계 | |
|---|---|
| 시가총액 | US$252.53m |
| 순이익 (TTM) | -US$95.65m |
| 매출 (TTM) | US$292.64m |
0.9x
주가매출비율(P/S)-2.6x
주가수익비율(P/E)OSG는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| OSG 손익계산서 (TTM) | |
|---|---|
| 매출 | US$292.64m |
| 매출원가 | US$115.37m |
| 총이익 | US$177.26m |
| 기타 비용 | US$272.92m |
| 순이익 | -US$95.65m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -2.13 |
| 총이익률 | 60.57% |
| 순이익률 | -32.69% |
| 부채/자본 비율 | 11.4% |
OSG의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/26 12:01 |
| 종가 | 2026/05/26 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Octave Specialty Group, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Giuliano Anderes Bologna | BTIG |
| Mary Kane | Citigroup Inc |
| Giuliano Anderes Bologna | Compass Point Research & Trading, LLC |